Back to Journals » OncoTargets and Therapy » Volume 11

Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients

Authors Wang LY, Cui JJ, Guo AX, Yin JY

Received 28 September 2017

Accepted for publication 5 December 2017

Published 24 January 2018 Volume 2018:11 Pages 529—538


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Carlos E Vigil

Video abstract presented by Lei-Yun Wang and Jia-Jia Cui.

Views: 152

Lei-Yun Wang,1,2 Jia-Jia Cui,1,2 Ao-Xiang Guo,1,2 Ji-Ye Yin1,2

1Department of Clinical Pharmacology, XiangYa Hospital, Central South University, Changsha, 2Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China

Abstract: Compared with various malignant tumors, lung cancer has high incidence and the highest mortality worldwide. Non-small-cell lung cancer (NSCLC), the most common kind of lung cancer, is still a great threat to the world, including China. Surgery, platinum-based chemotherapy, and radiotherapy are still the primary treatments for NSCLC patients in the clinic, whereas immunotherapy and targeted therapy are gradually playing more important roles. A next-generation tyrosine kinase inhibitor (TKI), afatinib, was developed as a targeted reagent for epidermal growth factor receptor (EGFR). This targeted drug was effective in a series of trials. The US Food and Drug Administration then approved afatinib as a new first-line treatment for EGFR L858R and exon 19 deletion mutant patients in 2013. This review focused on current clinical studies of afatinib. Although this TKI was not widely available in China until recently, we aim to provide a reference for its future use in China.

Keywords: afatinib, NSCLC, Chinese patients, drug resistance, side effect, companion diagnosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]